Cargando…

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

BACKGROUND: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing. METHODS: Seventeen patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, J-M, Sarosy, G A, Annunziata, C M, Azad, N, Minasian, L, Kotz, H, Squires, J, Houston, N, Kohn, E C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822947/ https://www.ncbi.nlm.nih.gov/pubmed/20051952 http://dx.doi.org/10.1038/sj.bjc.6605514

Ejemplares similares

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
por: Mouriaux, F, et al.
Publicado: (2016)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
por: Jain, Lokesh, et al.
Publicado: (2010)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
por: Cohen, Adam L., et al.
Publicado: (2020)

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
por: Alfaro, C, et al.
Publicado: (2009)

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
por: Bengala, C, et al.
Publicado: (2010)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults
por: Bodea, Jessica, et al.
Publicado: (2022)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109
por: Mina, Lida A., et al.
Publicado: (2013)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
por: Desar, I M E, et al.
Publicado: (2010)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
por: Tol, J., et al.
Publicado: (2008)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Impact of sorafenib on epidural fibrosis: An immunohistochemical study
por: Tanriverdi, Osman, et al.
Publicado: (2018)

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
por: Leighl, N B, et al.
Publicado: (2011)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
por: Dwojak, M, et al.
Publicado: (2015)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
por: Verstraete, M, et al.
Publicado: (2015)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
por: De Bruyne, S, et al.
Publicado: (2012)

A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
por: López, R, et al.
Publicado: (2010)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sr9k96ob2satfdfha3hpdlh7oh